What the ALOFT-IPF results mean for Bristol Myers Squibb and pulmonary fibrosis treatment
Bristol Myers Squibb's admilparant meets Phase 3 IPF endpoint at 60 mg, but 120 mg misses. Examine efficacy, safety and FDA prospects.
Pharma & Biotech
Pharma & Biotech
Boehringer Ingelheim expands Jascayd label to PPF following pivotal trial success
Boehringer Ingelheim has secured approval from the United States Food and Drug Administration for Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults. The decision follows earlier FDA clearance for Jascayd in idiopathic pulmonary fibrosis and now marks the first time a preferential PDE4B inhibitor with dual immunomodulatory and antifibrotic effects has